Sandvine Appoints Chief Ethics & Compliance Officer and Board Advisor as Part of Strengthened Commitment to Internet Freedom and Digital Rights
15.1.2025 18:41:00 CET | Business Wire | Press release
Carol Tate will serve as CCO following her tenure as Chief Compliance Officer at IntelFormer President & CEO of Human Rights First, Michael Breen, appointed as Advisor to the Board of Directors
Today, Sandvine (the “Company”), a market-leading provider of Over-the-Top (OTT) Application Classification and Quality of Experience (QoE) solutions, announced the appointments of Carol Tate as Chief Ethics & Compliance Officer, effective February 3, and Michael Breen as Advisor to the Board of Directors, effective January 1. Working closely with teams across the Company and in collaboration with its Board of Directors, Tate will spearhead compliance and due diligence initiatives to help facilitate Sandvine’s transition into a technology solution leader for democracies. Working directly with the Company’s Board of Directors, Breen is advising on human rights matters, including its engagement with non-governmental organizations to inform the Company’s human rights due diligence.
With decades of legal, risk, and compliance experience in the public and private sectors, Tate brings extensive experience embedding ethics and compliance into technological deployment and innovation on a global scale. She most recently served as Vice President and Chief Compliance Officer at Intel Corporation (NASDAQ: INTC) (“Intel”), where she led the organization’s global ethics and compliance function, which included driving initiatives to promote the company’s values and ethical culture, encourage open reporting, and reinforce Intel’s commitment to product responsibility in connection with Intel’s technology.
Prior to Intel, Tate held senior leadership roles within the ethics and compliance functions at McCarthy Holdings, Inc., Flextronics International Ltd., and Motorola. She also served as a senior attorney with the U.S. Securities and Exchange Commission’s Enforcement Division.
“As we operate in an increasingly complex digital environment, Sandvine’s focus on driving technological innovation while promoting internet freedom and digital rights could not be more critical,” said Tate. “I am excited to join a team and organization focused on providing high-quality products and premier customer service while facing these challenges head-on through close and productive partnerships with all stakeholders.”
Breen, an executive leader, strategist, policy expert and former military officer, has diverse experience leading complex organizations at the intersection of technology, global security, human rights, politics, and markets. He previously served as President & CEO of Human Rights First, a US-based organization confronting global human rights abuse, authoritarianism, and extremism through technology innovation and deployment, crisis response, policy development and advocacy, research, and legal services. Prior to leading Human Rights First, Breen acted as President & CEO of the Center for National Policy and the Truman National Security Project, served in the Obama administration’s Office of White House Counsel, and co-founded the International Refugee Assistance Project. He began his career as a decorated US Army officer, leading soldiers in combat in Iraq and Afghanistan.
“At a critical inflection point, Sandvine worked diligently to rechart its course, commit to being a positive and material contributor to the protection of human rights around the world, and double down on its mission to help people work, learn, entertain, and communicate. That resilience speaks to the Company’s potential to build itself into a values-driven technology solutions market leader,” said Breen. “I look forward to working closely with the Sandvine Board of Directors and the Company’s executive leadership team to help Sandvine navigate the challenges of today’s digital landscape.”
“Sandvine’s appointments of Carol and Michael are a direct reflection of the Company’s strengthened commitment to internet freedom and both digital and human rights, and we are honored to welcome them aboard,” added Carney Hawks, Chairman of the Board of Sandvine. “Carol’s extensive and successful track record collaborating with government and regulatory stakeholders, customers, trade groups, NGOs, and colleagues to deliver technological excellence governed by the highest ethical standards, combined with Michael’s exceptional background leading organizations dedicated to mitigating the world’s most complex issues across technology, human rights, global security and political dimensions, will be immensely valuable to Sandvine in this new chapter.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115186859/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom